Pharmacokinetics of Febuxostat in Healthy Chinese VolunteersLIU, X.-X; LIU, R.-J; DING, L et al.Arzneimittel-Forschung. 2012, Vol 62, Num 10, pp 463-469, issn 0004-4172, 7 p.Article

Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS techniqueKADIVAR, Mustakhusen H; PRAVEEN KUMAR SINHA; KUSHWAH, Dharmendra et al.Journal of pharmaceutical and biomedical analysis. 2011, Vol 56, Num 4, pp 749-757, issn 0731-7085, 9 p.Article

The effects of febuxostat on the pharmacokinetic parameters of rosiglitazone, a CYP2C8 substrateNAIK, Himanshu; WU, Jing-Tao; PALMER, Robert et al.British journal of clinical pharmacology. 2012, Vol 74, Num 2, pp 327-335, issn 0306-5251, 9 p.Article

Safety and Efficacy of Febuxostat Treatment in Subjects with Gout and Severe Allopurinol Adverse ReactionsCHOHAN, Saima.Journal of rheumatology. 2011, Vol 38, Num 9, pp 1957-1959, issn 0315-162X, 3 p.Article

Nouvel inhibiteur de la xanthine oxydase: Le fébuxostatDE BANDT, Michel.Rhumatos. 2010, Vol 7, Num 56, pp 92-96, issn 1771-0081, 5 p.Article

Les traitements pharmacologiques de la goutte : GOUTTE = Pharmacologic treatments of goutRICHETTE, P.La Lettre du rhumatologue. 2012, Num 384, pp 16-21, issn 0761-5027, 6 p.Article

The modern management of goutRIDER, Tom G; JORDAN, Kelsey M.Rheumatology (Oxford. Print). 2010, Vol 49, Num 1, pp 5-14, issn 1462-0324, 10 p.Article

Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjectsKHORSAVAN, Reza; GRABOWSKI, Brian; WU, Jing-Tao et al.British journal of clinical pharmacology. 2008, Vol 65, Num 3, pp 355-363, issn 0306-5251, 9 p.Article

Febuxostat : A selective xanthine oxidase inhibitor for the treatment of hyperuricemia and goutBRUCE, Susan P.The Annals of pharmacotherapy. 2006, Vol 40, Num 12, pp 2187-2194, issn 1060-0280, 8 p.Article

Febuxostat in the treatment of gout : 5-yr findings of the FOCUS efficacy and safety studySCHUMACHER, H. R; BECKER, M. A; LLOYD, E et al.Rheumatology (Oxford. Print). 2009, Vol 48, Num 2, pp 188-194, issn 1462-0324, 7 p.Article

Febuxostat: a new treatment for hyperuricaemia in goutEDWARDS, N. Lawrence.Rheumatology (Oxford. Print). 2009, Vol 48, issn 1462-0324, ii15-ii19, SUP2Article

Febuxostat: hepatic failurePrescrire international (Paris). 2013, Vol 22, Num 144, issn 1167-7422, p. 297Article

Women With Gout: Efficacy and Safety of Urate-Lowering With Febuxostat and AllopurinolCHOHAN, Saima; BECKER, Michael A; MACDONALD, Patricia A et al.Arthritis care and research. 2012, Vol 64, Num 2, pp 256-261, issn 0893-7524, 6 p.Article

Febuxostat : insuffisances hépatiquesLa Revue Prescrire. 2013, Vol 33, Num 359, issn 0247-7750, p. 667Article

FebuxostatHAIR, Philip I; MCCORMACK, Paul L; KEATING, Gillian M et al.Drugs (Basel). 2008, Vol 68, Num 13, pp 1865-1876, issn 0012-6667, 12 p.Article

Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney diseaseKANG, Y; KIM, M. J; JANG, H. N et al.Journal of clinical pharmacy and therapeutics (Print). 2014, Vol 39, Num 3, pp 328-330, issn 0269-4727, 3 p.Article

CArdiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComoRbiditiESWHITE, William B; CHOHAN, Saima; DABHOLKAR, Aruna et al.The American heart journal. 2012, Vol 164, Num 1, pp 14-20, issn 0002-8703, 7 p.Article

Synthesis of some 5-phenylisoxazole-3-carboxylic acid derivatives as potent xanthine oxidase inhibitorsSHAOJIE WANG; JUFANG YAN; JIAN WANG et al.European journal of medicinal chemistry. 2010, Vol 45, Num 6, pp 2663-2670, issn 0223-5234, 8 p.Article

Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and UnderexcretorsGOLDFARB, David S; MACDONALD, Patricia A; HUNT, Barbara et al.Journal of rheumatology. 2011, Vol 38, Num 7, pp 1385-1389, issn 0315-162X, 5 p.Article

Goutte: mise en place et suivi du traitement hypo-uricémiantRICHETTE, Pascal.Revue du rhumatisme (Ed. française). 2011, Vol 78, issn 1169-8330, S142-S147, SUP3Article

Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemiaSANCHEZ-LOZADA, Laura G; TAPIA, Edilia; SOTO, Virgilia et al.Nephrology, dialysis, transplantation (Print). 2008, Vol 23, Num 4, pp 1179-1185, issn 0931-0509, 7 p.Article

Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-AnalysisPENG YE; SHUMIN YANG; WENLONG ZHANG et al.Clinical therapeutics. 2013, Vol 35, Num 2, pp 180-189, issn 0149-2918, 10 p.Article

Les traitements de la goutte Molécules actuelles et à venir = Advances in gout therapyCHALES, Gérard; GUGGENBUHL, Pascal.Rhumatos. 2010, Vol 7, Num 57, issn 1771-0081, 126-132 [6 p.]Article

Urate-Lowering Therapy for Gout: Focus on FebuxostatLOVE, Bryan L; BARRONS, Robert; VEVERKA, Angie et al.Pharmacotherapy. 2010, Vol 30, Num 6, pp 594-608, issn 0277-0008, 15 p.Article

Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney diseaseKOBAYASHI, S; OGURA, M; HOSOYA, T et al.Journal of clinical pharmacy and therapeutics (Print). 2013, Vol 38, Num 3, pp 258-261, issn 0269-4727, 4 p.Article